1. Inicio
  2. Investigación
  3. Grupos de investigación
  4. Investigación quirúrgica en urología y trasplante renal

Investigación quirúrgica en urología y trasplante renal

Buscador de publicaciones

Sólo se han incluido artículos originales, editoriales y revisiones.

  • Scilipoti P, Longoni M, de Angelis M, Zaurito P, Slusarczyk A, Soria F, Pradere B, Krajewski W, D'Andrea D, Mari A, Del Giudice F, Pichler R, Subiela JD, Marcq G, Gallioli A, Afferi L, Mastroianni R, Simone G, Albisinni S, Mertens LS, Laukhtina E, Oberneder K, Rodríguez Elena JL, Aranda J, Puentedura AL, Caño Velasco J, Contieri R, Hurle R, Mori K, Radziszewski P, Shariat SF, Gontero P, Necchi A, Rouprêt M, Montorsi F, Salonia A, Briganti A, Moschini M.

    Outcomes of BCG vs upfront radical cystectomy for high-risk non-muscle-invasive bladder cancer.

    BJU INTERNATIONAL . 136(1): 47-54.

    [doi:10.1111/bju.16675]

  • Carnero-Alcázar M, Nuñez-Gil IJ, Vilacosta I, Montero L, Cuerpo G, Lopez-Menendez J, Feltes-Guzman G, Beltrao-Sial R, Pérez-Camargo D, Vicedo-López Á, Miranda-Torrón J, Solís-Chávez MB, Cobiella J, Maroto L.

    Need for a permanent pacemaker after transcatheter aortic valve implantation in Spain: a retrospective analysis of the national Minimum Basic Dataset from 2017 to 2022.

    Open Heart . 12(1): .

    [doi:10.1136/openhrt-2025-003396]

  • Pichler R, van Creij NCH, Subiela JD, Cimadamore A, Caño-Velasco J, Tully KH, Mori K, Contieri R, Afferi L, Mari A, Soria F, Del Giudice F, D'Elia C, Mayr R, Mertens LS, Pyrgidis N, Moschini M, Gallioli A.

    Biological and therapeutic implications of FGFR alterations in urothelial cancer: A systematic review from non-muscle-invasive to metastatic disease.

    Actas Urologicas Espanolas . 49(5): 501719-501719.

    [doi:10.1016/j.acuroe.2025.501719]

  • Scilipoti P, Longoni M, de Angelis M, Zaurito P, Massiet A, Dutto D, Soria F, Álvarez-Maestro M, Bazán AA, Pradere B, Klatte T, Contieri R, Hurle R, Krajewski W, Subiela JD, Pichler R, Szostek A, Marcq G, Elena JLR, Aranda J, Gontero P, Rouprêt M, Shariat SF, Necchi A, Montorsi F, Briganti A, Xylinas E, Moschini M.

    Gemcitabine and docetaxel for high-risk non-muscle-invasive bladder cancer: EuroGemDoce group results.

    BJU INTERNATIONAL . 135(6): 969-976.

    [doi:10.1111/bju.16645]

  • Albers Acosta E, Pelari-Mici L, Celada Luis G, Velasco Balanza C, Zapatero A, Romero-Laorden N, Toquero Diez P, Caño-Velasco J, Guerrero-Ramos F, Moschini M, Krajewski W, Del Giudice F, Soria F, Laukhtina E, Mertens L, Pichler R, Mori K, D'Andrea D, Mari A, Marcq G, Teoh J, Afferi L, Albisinni S, Pradere B, Gallioli A, Subiela JD, San José Manso L.

    The impact of a multidisciplinary approach on treatment decisions and outcomes in urothelial carcinoma: A systematic review.

    Actas Urologicas Espanolas . 49(5): 501718-501718.

    [doi:10.1016/j.acuroe.2025.501718]

  • Santoni M, Roviello G, Grande E, De Giorgi U, Fiala O, Seront E, Molina-Cerrillo J, Pichler R, Myint ZW, Kucharz J, Kanesvaran R, Büttner T, Pichler M, Basso U, Kopecky J, Bourlon MT, Cerbone L, Buchler T, Pinto A, de Liaño AG, Gianni C, Zgura A, Rescigno P, Ansari J, Caffo O, Küronya Z, Vitale MG, Bhuva D, Catalano M, Vau N, Kopp RM, Buti S, Bamias A, Porta C, Sunela K, Massari F.

    Pembrolizumab-axitinib versus nivolumab-cabozantinib as first-line therapy in patients with metastatic renal cell carcinoma: a retrospective real-world comparison (ARON-1).

    CANCER IMMUNOLOGY IMMUNOTHERAPY . 74(7): 225-225.

    [doi:10.1007/s00262-025-04043-x]

  • Gómez Rivas J, de la Parra I, Infante S, Ibañez L, Gutierrez Hidalgo B, Cabrera MN, Puente J, Sanmamed N, Ortega Polledo LE, Galante MI, Moreno Sierra J.

    Prostate-Specific Membrane Antigen Positron Emission Tomography (PSMA-PET) in Initial Staging of Prostate Cancer Patients: The Beginning of a New Era.

    MEDICINA-LITHUANIA . 61(5): .

    [doi:10.3390/medicina61050924]

  • Porta C, Massari F, Taha T, Grande E, Bourlon MT, Kanesvaran R, Basso U, Molina-Cerrillo J, Alonso-Gordoa T, Myint ZW, Fornarini G, Buttner T, Park SH, Ürün Y, De Giorgi U, Pichler R, Rescigno P, Buchler T, Studentova H, Melichar B, Ansari J, Mollica V, Kucharz J, Rizzo M, Rizzo A, Kopp RM, Buti S, Monteiro FSM, Soares A, Bamias A, Santoni M.

    Pembrolizumab plus Lenvatinib in patients with metastatic Renal Cell Carcinoma: real-world evidences from the international ARON- 1 study.

    CANCER IMMUNOLOGY IMMUNOTHERAPY . 74(7): 196-196.

    [doi:10.1007/s00262-025-04019-x]

  • Alonso-Gordoa T, Anguera G, Domínguez-Esteban M, Reig Ò, Martínez-Barros H, Molina-Cerrillo J, Cruz P, Maroto P.

    Expert consensus on patterns of progression in kidney cancer after adjuvant immunotherapy and subsequent treatment strategies.

    CANCER TREATMENT REVIEWS . 136: 102925-102925.

    [doi:10.1016/j.ctrv.2025.102925]

  • Rodríguez-Moreno JF, de Velasco G, Álvarez-Fernández C, Collado R, Fernández R, Vázquez S, Virizuela JA, Gajate P, Font A, Lainez N, Sevillano-Fernández E, Graña-Castro O, Beltrán L, Madurga R, Rodríguez-Antona C, Berraondo P, Ruiz-Llorente S, García-Donas J.

    Treatment Efficacy and Molecular Dynamics of Neoadjuvant Durvalumab and Olaparib in Resectable Urothelial Bladder Cancer: The NEODURVARIB Trial.

    CLINICAL CANCER RESEARCH . 31(9): 1644-1656.

    [doi:10.1158/1078-0432.CCR-24-2890]

  • Laszkiewicz J, Del Giudice F, Li S, Krajewski W, Nowak L, Szydelko T, Basran S, De Berardinis E, Carino D, Corvino R, Santerelli V, Ferro M, Rocco B, Sighinolfi MC, Crocetto F, Barone B, Dinacci F, Pichler R, Subiela JD, Pradere B, Moschini M, Mari A, Gallioli A, Mori K, Soria F, Mertens L, Abu-Ghanem Y, Nair R, Khan MS, Chung BI.

    Novel risk factors for venous thromboembolism following outpatient or inpatient transurethral resection of bladder tumors: Multivariable stepwise and LASSO regression modeling from us insurance claim database.

    Actas Urologicas Espanolas . 49(4): 501738-501738.

    [doi:10.1016/j.acuroe.2025.501738]

  • Rivero Belenchón I, Congregado Ruíz CB, Gómez Ciriza G, Gómez Dos Santos V, Burgos Revilla FJ, Medina López RA.

    Impact of 3D-Printed Models for Surgical Planning in Renal Cell Carcinoma With Venous Tumor Thrombus: A Randomized Multicenter Clinical Trial.

    JOURNAL OF UROLOGY . 213(5): 568-580.

    [doi:10.1097/JU.0000000000004425]

  • Artero Fullana S, Caño Velasco J, Lafuente Puentedura A, Polanco Pujol L, Bataller Monfort V, Moralejo Gárate M, Subiela JD, Gallioli A, Moschini M, Pichler R, Del Giudice F, Marcq G, Teoh J, Soria F, Mertens L, Krajewski W, Laukhtina E, Mori K, Pradere B, Afferi L, Tully KH, Albisinni S, Abu Ghanem Y, d'Andrea D, Mari A, Albers Acosta E, Contieri R, Cimadamore A, Grobet-Jeandin E, Gómez Rivas J, Hernández Fernández C.

    Diagnostic accuracy of Bladder EpiCheck for upper tract urothelial carcinoma: A meta-analysis.

    Actas Urologicas Espanolas . 49(4): 501720-501720.

    [doi:10.1016/j.acuroe.2025.501720]

  • Capdevila J, Pubul V, Anido U, Walter T, Molina-Cerrillo J, Alonso-Gordoa T, Garcia-Carbonero R, San-Roman-Gil M, Llana B, Jimenez-Fonseca P, Benavent Viñuales M, Ansquer C, Baudin E, Lepage C, Del Olmo-García M, Ruffinelli JC, Beron A, Haissaguerre M, Deshayes E, Taïeb D, Baldari S, Sansovini M, Cingarlini S, Filice A, Panzuto F, Álvarez-Álvarez R, Lousberg L, Aboubakar Nana F, Hernando J, García-Álvarez A, García-Burillo A, Villacampa G, Vandamme T, Fazio N, Durand A.

    A Randomized clinical trial evaluating the impact on survival and quality of life of (177)Lutetium[Lu]-edotreotide versus everolimus in patients with neuroendocrine tumors of the lung and thymus: the LEVEL study (GETNE T-2217).

    Bmc Cancer . 25(1): 613-613.

    [doi:10.1186/s12885-025-13941-3]

  • Gómez Del Val A, Sánchez A, Freire-Agulleiro Ó, Martínez MP, Muñoz M, Olmos L, Medina JS, Comerma-Steffensen SG, Simonsen U, Rivera L, López M, Contreras C, Prieto D.

    Penile endothelial dysfunction, impaired redox metabolism and blunted mitochondrial bioenergetics in diet-induced obesity: Compensatory role of H(2)O(2).

    FREE RADICAL BIOLOGY AND MEDICINE . 230: 222-233.

    [doi:10.1016/j.freeradbiomed.2025.02.004]

  • Pal SK, Powles T, Kanesvaran R, Molina-Cerrillo J, Feldman DR, Barata P, Liu M, Bhatt A, Wang Z, Nandoskar P, Suarez C.

    STELLAR-304: a phase III study of zanzalintinib (XL092) plus nivolumab in advanced non-clear cell renal cell carcinoma.

    FUTURE ONCOLOGY . 21(7): 1-8.

    [doi:10.1080/14796694.2025.2458395]

  • Fiala O, Buti S, Fujita K, de Liaño AG, Fukuokaya W, Kimura T, Yanagisawa T, Giannatempo P, Angel M, Mennitto A, Molina-Cerrillo J, Bourlon MT, Soares A, Takeshita H, Calabrò F, Ortega C, Kucharz J, Milella M, Seront E, Park SH, Tural D, Benedetti G, Ürün Y, Battelli N, Melichar B, Poprach A, Buchler T, Kopecký J, Conteduca V, Monteiro FSM, Massari F, Gupta S, Santoni M.

    Concomitant medications in patients with metastatic urothelial carcinoma receiving enfortumab vedotin: real-world data from the ARON-2(EV) study.

    CLINICAL & EXPERIMENTAL METASTASIS . 42(2): 18-18.

    [doi:10.1007/s10585-025-10335-4]

  • Del Olmo-García M, Hernandez-Rienda L, Garcia-Carbonero R, Hernando J, Custodio A, Anton-Pascual B, Gomez M, Palma Milla S, Suarez L, Bellver M, Alonso V, Serrano R, Valdés N, Melian M, Febrero B, Sampedro-Nuñez MA, Biarnes J, Díaz-Pérez JÁ, Molina-Cerrillo J, Lopez C, Martínez Olmos MÁ, Merino-Torres JF, Capdevila J, Argente Pla M.

    Nutritional status and quality of life of patients with advanced gastroenteropancreatic neuroendocrine neoplasms in Spain: the NUTRIGETNE (GETNE-S2109) study.

    ONCOLOGIST . 30(2): .

    [doi:10.1093/oncolo/oyae343]